ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Telix Pharmaceuticals Limited announced that safety and tolerability data from the Part 1 lead-in of its Phase 3 ProstACT Global trial evaluating its PSMA-targeted lutetium radio antibody-drug conjugate (TLX591-Tx) in metastatic castration-resistant prostate cancer will be presented as a late-breaking abstract at ASCO 2026. The international ProstA…